Cagrilintide
Cagrilintide Acetate • Also called Cagri, Cagrilintide Acetate
Cagrilintide is increasingly searched alongside newer weight-loss peptides, but FDA has identified cagrilintide acetate as ineligible for human drug compounding under section 503A.
Current status
Restricted
Weight-management interest, with current federal compounding constraints still in play.
FDA category
Not on 503A bulks list
Can pharmacies compound this?
No
Reclassification expected?
Unclear
Interest is moving faster than the lawful compounding path. The current federal signal is a direct ineligibility problem, not a soft review status.
Primary Use
Weight-management interest
Also searched as
Cagri, Cagrilintide Acetate
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Dec 8, 2025
Current status signal recorded: FDA warning-letter posture identifies cagrilintide acetate as ineligible for use in human drug compounding under section 503A..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Cagrilintide status changes
State-specific notes
California
Novel metabolic peptides face especially conservative sourcing when the 503A basis is weak.